Searchable abstracts of presentations at key conferences in endocrinology

ea0099ep571 | Reproductive and Developmental Endocrinology | ECE2024

Short and long-term efficacy of minoxidil on beard growth in a group of assigned female at birth transgender people on gender affirming hormone therapy

Marinelli Lorenzo , Bichiri Andreina , Ghigo Ezio , Motta Giovanna

Introduction: Minoxidil is a vasodilator drug used as topical treatment of androgenetic alopecia; however, its efficacy for beard enhancement is reported in cisgender men and in a case-report of a transgender assigned female at birth (t-AFAB) adolescent. This study aims to evaluate the short- and long-term efficacy of topical minoxidil in a group of t-AFAB people on gender affirming hormone therapy (GAHT) with testosterone.Materials and methods:...

ea0102100 | Reproductive Endocrinology | EYES2024

Short-term changes in bone metabolism among transgender men starting gender affirming hormone therapy: a systematic review and meta-analysis

Marinelli Lorenzo , Tienforti Daniele , Vervalcke Jeroen , Bichiri Andreina , T'Sjoen Guy , Motta Giovanna , Barbonetti Arcangelo

Introduction: Transgender and gender diverse (TGD) people experience a gender identity which is different from the sex assigned at birth. Some transgender men (TM) can ask for testosterone to induce virilization and its effects on bone health are still to be fully elucidated. The aim of this systematic review and meta-analysis was to evaluate the changes on bone metabolism in a short-term period among TM starting testosterone. Methods: A systematic searc...

ea0090oc4.1 | Oral Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Gender-affirming hormone treatment: friend or foe? Long term follow-up of 755 transgender and gender diverse people

Spaggiari Giorgia , Marinelli Lorenzo , Cacciani Marta , Scipio Sofia , Bichiri Andreina , Profeta Alessandra , Granata Antonio Raffaele Michele , Ghigo Ezio , Simoni Manuela , Motta Giovanna , Santi Daniele

Background: Gender-affirming hormone treatment (GAHT) is the cornerstone in the therapeutic management of transgender and gender diverse (TGD) people, which are currently classified as transgender assigned-female-at birth (t-AFAB) and assigned-male-at birth (t-AMAB) subjects. Due to its hormonal nature, GAHT is commonly handled by the endocrinologist and available guidelines on this topic mimic the recommendations for cis-gender hypogonadal populations. However, the GAHT long ...